Skip to content

Study · Systematic review · 2021

1 result

Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials.

Wei XB, Wei W, Ding LL, Liu SY

Primary care diabetes8 Sept 2020Cited by 33 (Europe PMC)

PMID32912710 (opens in a new tab)DOI10.1016/j.pcd.2020.08.017 (opens in a new tab)PepBankPUB-32912710
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide significantly reduced MACE versus lixisenatide (HR 0.73).

    In plain wordsIn adults with type 2 diabetes, semaglutide injections lowered major heart events compared with lixisenatide.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE versus lixisenatide
    Study

    n: not reported in source

    Comparator
    Lixisenatide
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous semaglutide (HR 0.73, 95% CI 0.55-0.96)
    2 context sentences
    Summary · context
    The relative efficacy of different sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in reducing cardiorenal events in type 2 diabetic adults is unclear.
    Summary · context
    Three primary endpoints were major adverse cardiovascular events (MACE), hospitalization for heart failure (HHF), and kidney function progression (KFP).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 5Current

    27 Oct 2026, 16:36 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 18:59 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 3

    12 Oct 2026, 12:10 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.